GSK Pfizer Joint Venture No Impact on Company Value |
Equity Research & Insights |
Damien Conover, CFA |
20/12/18 |
Novartis Deal Will Strengthen Glaxo's Dividend say Analysts |
Equity Research & Insights |
Damien Conover, CFA |
28/03/18 |
Pfizer Offers Dividend Opportunity |
Equity Research & Insights |
Damien Conover, CFA |
07/06/17 |
Market Outlook: Healthcare Stocks |
Equity Research & Insights |
Damien Conover, CFA |
13/04/17 |
What Does President Trump Mean for Healthcare Stocks? |
Equity Research & Insights |
Damien Conover, CFA |
10/11/16 |
AstraZeneca Shares Upgraded Thanks to Weak Sterling |
Equity Research & Insights |
Damien Conover, CFA |
24/10/16 |
AstraZeneca Fairly Valued after Solid Q3 |
Equity Research & Insights |
Damien Conover, CFA |
10/11/15 |
Pharmaceutical Stocks Get Sales Boost from Clinical Report |
Equity Research & Insights |
Damien Conover, CFA |
15/05/15 |
Investment Focus: AstraZeneca |
Equity Research & Insights |
Damien Conover, CFA |
12/05/15 |
AstraZeneca is Overvalued |
Equity Research & Insights |
Damien Conover, CFA |
27/04/15 |
Is Glaxo's Dividend at Risk? |
Equity Research & Insights |
Damien Conover, CFA |
05/02/15 |
What's in the Pipeline for AstraZeneca |
Equity Research & Insights |
Damien Conover, CFA |
07/11/14 |
British Pharmaceutical Companies Lag Global Peers |
Equity Research & Insights |
Damien Conover, CFA |
04/11/14 |
Astra Shares Worth £35 |
Equity Research & Insights |
Damien Conover, CFA |
04/06/14 |
Astra Overvalues Prospects |
Equity Research & Insights |
Damien Conover, CFA |
07/05/14 |
Analyst View: AstraZeneca Merger |
Equity Research & Insights |
Damien Conover, CFA |
28/04/14 |
GlaxoSmithKline Undervalued, say Analysts |
Equity Research & Insights |
Damien Conover, CFA |
11/12/13 |
GlaxoSmithKline is Undervalued, say Analysts |
Equity Research & Insights |
Damien Conover, CFA |
28/10/13 |
AstraZeneca Undervalued, say Analysts |
Equity Research & Insights |
Damien Conover, CFA |
09/10/13 |
GlaxoSmithKline Retains its Competitive Advantage |
Equity Research & Insights |
Damien Conover, CFA |
19/08/13 |
AstraZeneca is "Undervalued" Say Analysts |
Equity Research & Insights |
Damien Conover, CFA |
08/08/13 |
Boosting Big Pharma Valuations on Lower Cost of Equity Assumptions |
Equity Research & Insights |
Damien Conover, CFA |
03/06/13 |
Improving Long-Term Outlook for Big Pharma in 2013 |
Equity Research & Insights |
Damien Conover, CFA |
22/01/13 |
Amylin Purchase Makes Sense for AstraZeneca |
Equity Research & Insights |
Damien Conover, CFA |
03/07/12 |
AstraZeneca and Pfizer to Lead Big Pharma M&A |
Premium Exclusive |
Damien Conover, CFA |
22/03/12 |
Can AstraZeneca Navigate Its Pipeline Waters? |
Equity Research & Insights |
Damien Conover, CFA |
06/01/12 |
Emerging Markets Keep Astra on Top of Patent Cliff |
Equity Research & Insights |
Damien Conover, CFA |
29/07/11 |
New Drugs Help GSK Offset Generic Competition |
Equity Research & Insights |
Damien Conover, CFA |
28/07/11 |
Tax Settlement Helps AstraZeneca Post In-line 1Q |
Equity Research & Insights |
Damien Conover, CFA |
28/04/11 |
Mixed 1Q from Glaxo as Weak Sales Weigh on Growth |
Equity Research & Insights |
Damien Conover, CFA |
28/04/11 |
AstraZeneca Positioned to Offset Patent Losses |
Equity Research & Insights |
Damien Conover, CFA |
04/03/11 |
Can Glaxo Withstand Generic Competition? |
Equity Research & Insights |
Damien Conover, CFA |
07/02/11 |
Glaxo's Stock Buyback Plan Signals Undervaluation |
Equity Research & Insights |
Damien Conover, CFA |
03/02/11 |
Astra Posts Solid 4Q but Lowers Long-Term Outlook |
Equity Research & Insights |
Damien Conover, CFA |
27/01/11 |
Still 80% Chance of Approval for Astra’s Brilinta |
Equity Research & Insights |
Damien Conover, CFA |
20/12/10 |
AstraZeneca Likely to Hit the Top of its Guidance |
Equity Research & Insights |
Damien Conover, CFA |
28/10/10 |
Glaxo's 3Q Earnings Hit by Avandia Charges |
Equity Research & Insights |
Damien Conover, CFA |
22/10/10 |
Swings and Roundabouts In the Pharma Industry |
Equity Research & Insights |
Damien Conover, CFA |
27/09/10 |
Agencies React Negatively to Avandia |
Equity Research & Insights |
Damien Conover, CFA |
24/09/10 |
Sanofi Can Stretch Further to Secure Genzyme |
Equity Research & Insights |
Damien Conover, CFA |
31/08/10 |
Favourable 2Q and Panel Vote for AstraZeneca |
Equity Research & Insights |
Damien Conover, CFA |
29/07/10 |
Glaxo's 2Q Tops Expectations |
Equity Research & Insights |
Damien Conover, CFA |
21/07/10 |
GlaxoSmithKline Can Swallow Bitter Pill |
Equity Research & Insights |
Damien Conover, CFA |
16/07/10 |
Big Pharma Outlook for 2Q and Beyond |
Equity Research & Insights |
Damien Conover, CFA |
13/07/10 |
Toprol and Tax Gains Buoy Astra's 1Q |
Equity Research & Insights |
Damien Conover, CFA |
30/04/10 |
Vaccine Sales Aid GlaxoSmithKline's 1Q |
Equity Research & Insights |
Damien Conover, CFA |
29/04/10 |
Glaxo takes steps to improve long-term prospects |
Equity Research & Insights |
Damien Conover, CFA |
10/02/10 |
Trends so far in big pharma's fourth quarter |
Equity Research & Insights |
Damien Conover, CFA |
01/02/10 |
AstraZeneca issues disappointing guidance |
Equity Research & Insights |
Damien Conover, CFA |
28/01/10 |
The 2010 outlook for big pharma stocks |
Equity Research & Insights |
Damien Conover, CFA |
21/01/10 |